Tab Article

• 1000 plus corrections/updates are added with complete revision/correction of 300 plus tables in the book.
• Major revision in interpretation of AST Chapter as per latest guidelines from CLSI and EUCAST incorporating several updates such as
  • Tier system of CLSI, update in the list of SDD and ECV
  • Update in the clinical breakpoints including Salmonella/Shigella breakpoint table
  • Update in the reporting of fosfomycin, aminoglycosides, CZA-ATM synergy
  • Update on AST reporting of B. cepacia, B. pseudomallei, Stenotrophomonas, A. baumannii
  • Update on treatment recommendations for invasive enterococcal infections
• Updates on Treatment guidelines and Dosing Regimens.
• New Duke's criteria 2023 for IE.
• Major update: A new Module on ‘Decision to be taken on VITEK-AES modifications’.
• Major update: A new Practical Module in Validation of Antibiogram based on general acceptable S% rules (with new exercise).
• Major update: Practical Module on Pathogen-directed (PD) AMS audit.
• Updates in list of drugs in AWaRe classification.
  • Revised definitions on antimicrobial consumption (AMC) and antimicrobial use (AMU)
  • Major updates on— fosfomycin and CZA-ATM synergy testing methods, AmpC detection methods etc.
• Major updates on BMQ and MIC guiding tables and selective reporting.
• >40 newer antimicrobials have been incorporated in every chapter of Antimicrobial Section such as newer β-lactams and BLBLI, newer aminoglycosides, newer tetracyclines, newer quinolones and several novel antimicrobials.
• A major revision has been carried on treatment of tuberculosis chapter.
• Major revision on chapters on ‘Targeted therapy for GNB and GPC’.